SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Sigma Labs Inc (OTCMKTS:SGLB) witnessed a strong start in April. The company’s stock price has already gained 40% since the end of March and volume is constantly rising, with monthly average being shifted drastically for three consecutive days. On Monday, the stock surged 7% to close the day at $0.12 per share on share volume of 7.4 million. However, it pulled back marginally in last trading session with decline of 0.83%. The closing price was $0.119 and volume for the day stood at 3.15 million compared to average volume of 2.02 million.

The annual report

Sigma Labs Inc (OTCMKTS:SGLB) released its annual report for FY2014 in last week of March. As per the report, the company had $2.96 million in cash as of December 2014. The total liabilities came at $354,000 while the annual revenue was $548,000. The annual net loss was $3.1 million. The encouraging part is that despite the low revenue, the company is not loaded with heavy debt.

No problem of dilution

Even it has not opted for any heavy dilution in the last quarter of 2014. The outstanding shares count in November 2014 stood at 618 million whereas it was marginally up to 623 million as of March 31, 2015. The fundamentals have remained strong for Sigma Labs.

Product launch

Apart from the financial numbers, the company launched an event on April 14, 2015 to present the M290 additive printer. It is manufactured by German e-Manufacturing Solutions. It was initially introduced in the spring of 2014 and the latest launch was a considerably overhauled version. The new product contained Sigma’s proprietary IPQA technology.

The takeaway

Investors have been waiting eagerly for the commercial launch of the new product. However, it is necessary to take caution at the current levels as the stock price is trading deep into overbought territory and has been there for a quite time now.